Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S64315 and Azacitidine in AML
NCT04629443Phase 2Completed
- Sponsor
- Servier
- Start
- Feb 2021
- Primary completion
- Aug 2023
- Countries
- 4
01
Overview
Phase 2, open-label trial of S64315 in acute myeloid leukemia (AML), sponsored by Servier. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Feb 2021; status: completed.
02
Drugs
S64315
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04629443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629443.